Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection

被引:0
|
作者
Marina Rankovic
Nevena Jeremic
Ivan Srejovic
Katarina Radonjic
Aleksandra Stojanovic
Milos Glisic
Stefani Bolevich
Sergey Bolevich
Vladimir Jakovljevic
机构
[1] University of Kragujevac,Department of Pharmacy, Faculty of Medical Sciences
[2] University of Kragujevac,Department of Physiology, Faculty of Medical Sciences
[3] 1st Moscow State Medical University IM Sechenov,Department of Pathophysiology
[4] 1st Moscow State Medical University IM Sechenov,Department of Human Pathology
来源
Heart Failure Reviews | 2021年 / 26卷
关键词
DPP-4 inhibitors; Diabetes; Ischaemic-reperfusion injury; Cardioprotection;
D O I
暂无
中图分类号
学科分类号
摘要
Previous studies have demonstrated that individuals with type 2 diabetes mellitus (T2DM) have a two- to fourfold propensity to develop cardiovascular disease (CVD) than nondiabetic population, making CVD a major cause of death and disability among people with T2DM. The present treatment options for management of diabetes propose the earlier and more frequent use of new antidiabetic drugs that could control hyperglycaemia and reduce the risk of cardiovascular events. Findings from basic and clinical studies pointed out DPP-4 inhibitors as potentially novel pharmacological tools for cardioprotection. There is a growing body of evidence suggesting that these drugs have ability to protect the heart against acute ischaemia-reperfusion injury as well as reduce the size of infarction. Consequently, the prevention of degradation of the incretin hormones by the use of DPP-4 inhibitors represents a new strategy in the treatment of patients with T2DM and reduction of CV events in these patients. Here, we discuss the cardioprotective effects of DPP-4 inhibitors as well as proposed pathways that these hypoglycaemic agents target in the cardiovascular system.
引用
收藏
页码:437 / 450
页数:13
相关论文
共 50 条
  • [31] Synthesis of dipeptidyl peptidase-4 inhibitors: a brief overview
    Mulakayala, Naveen
    Reddy, Upendar C. H.
    Iqbal, Javed
    Pal, Manojit
    TETRAHEDRON, 2010, 66 (27-28) : 4919 - 4938
  • [32] Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
    Hong, Sangmo
    Jung, Chang Hee
    Han, Song
    Park, Cheol-Young
    DIABETES & METABOLISM JOURNAL, 2022, 46 (01) : 63 - +
  • [33] Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors
    Tulipano, Giovanni
    Sibilia, Valeria
    Caroli, Anna Maria
    Cocchi, Daniela
    PEPTIDES, 2011, 32 (04) : 835 - 838
  • [34] The role of dipeptidyl peptidase-4 inhibitors in diabetic kidney disease
    Panchapakesan, Usha
    Pollock, Carol
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [35] Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Risk Analysis
    Vardarli, I.
    Ozcelik, C.
    KARDIOLOGE, 2014, 8 (06): : 448 - 450
  • [36] Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2015, 4 : 19 - 24
  • [37] Determination of Dipeptidyl Peptidase-4 Inhibitors by Spectrophotometric and Chromatographic Methods
    P. B. Deshpande
    S. R. Butle
    Journal of Analytical Chemistry, 2018, 73 : 303 - 316
  • [38] Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?
    Giuseppe Paolisso
    Matteo Monami
    Raffaele Marfella
    Maria Rosaria Rizzo
    Edoardo Mannucci
    Advances in Therapy, 2012, 29 : 218 - 233
  • [39] URATE-LOWERING EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
    Panevin, Taras S.
    Zhelyabina, Olga, V
    Eliseev, Maxim S.
    Shestakova, Marina, V
    DIABETES MELLITUS, 2020, 23 (04): : 349 - 356
  • [40] Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
    Cheng, Qi
    Cheng, Jinluo
    Cordato, Dennis
    Gao, Jianqun
    PHARMACOLOGY & THERAPEUTICS, 2020, 212